ML-7 Hydrochloride: Selective MLCK Inhibitor for Cardiovascular Research

Executive Summary: ML-7 hydrochloride (A3626, APExBIO) is a selective inhibitor of myosin light chain kinase (MLCK) with a Ki of 300 nM, enabling precise regulation of myosin light chain phosphorylation in muscle contractility assays (APExBIO product page). The compound is highly soluble in DMSO (≥15.95 mg/mL) and water (≥8.82 mg/mL) but insoluble in ethanol, supporting flexible in vitro and in vivo applications. ML-7 improves cardiac contractility and modulates metabolic and oxidative stress proteins in ischemia/reperfusion (I/R) animal models (Protein Kinase C article). It also regulates tight junction proteins to ameliorate vascular endothelial dysfunction and atherosclerosis in rabbit models. ML-7’s role as a pathway-specific tool is supported by both peer-reviewed benchmarks and reproducible product specifications (purity ~98%, short-term solution stability at -20°C).

Biological Rationale

Myosin light chain kinase (MLCK) is a serine/threonine protein kinase that regulates phosphorylation of myosin light chain (MLC), a critical step for actin-myosin cross-bridge cycling in both smooth and cardiac muscle. MLCK activity governs muscle contraction, cellular motility, tight junction dynamics, and vascular integrity. Dysregulation of MLCK-mediated pathways is implicated in cardiovascular diseases, including ischemia/reperfusion (I/R) injury and atherosclerosis (Phosphatase Inhibitor article). Targeted inhibition of MLCK provides a mechanistic probe for dissecting these pathologies. ML-7 hydrochloride is widely used to selectively block MLCK activity without broad-spectrum kinase inhibition, distinguishing it from less selective agents. This specificity supports its adoption in advanced cardiovascular, vascular dysfunction, and endothelial barrier research.

Mechanism of Action of ML-7 hydrochloride

ML-7 hydrochloride (1-((5-iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride) inhibits MLCK by competitively binding the ATP-binding site, suppressing kinase-mediated MLC phosphorylation. The Ki for MLCK inhibition is 300 nM under standard in vitro kinase assay conditions (pH 7.4, 25°C, ATP 100 µM). By preventing MLC phosphorylation, ML-7 blocks actin-myosin interactions essential for muscle contraction and cytoskeletal reorganization. This mechanism underpins its use in studies of muscle contractility, endothelial barrier function, and cytoskeletal dynamics (Wei et al., 2019). ML-7 also indirectly modulates tight junction proteins such as ZO1 and occludin by inhibiting MLCK-driven phosphorylation cascades in vascular endothelium.

Evidence & Benchmarks

• ML-7 hydrochloride inhibits MLCK with a Ki of 300 nM, as determined by in vitro enzymatic assays (APExBIO Specification Sheet: product page).
• In neonatal rat cardiomyocytes, ML-7 (10 µM, 37°C, 24 h) blocks sarcomeric reorganization induced by recombinant human neuregulin-1, elucidating its role in cardiac cellular modulation (Protein Kinase A Inhibitor article).
• Pre-ischemia and reperfusion administration of ML-7 (3 mg/kg, intravenous) in rat I/R models significantly enhances left ventricular contractility and reduces myocardial infarct size (Protein Kinase C article).
• ML-7 treatment improves endothelial barrier function in rabbit atherosclerosis models by upregulating tight junction proteins ZO1 and occludin (dose: 1 mg/kg, i.v., 6 weeks) (Wei et al., 2019).
• ML-7 is soluble to ≥15.95 mg/mL in DMSO and ≥8.82 mg/mL in water with ultrasonic treatment; insoluble in ethanol (APExBIO, product page).
• Purity of supplied ML-7 hydrochloride is ~98% (HPLC), with recommended storage at -20°C to maintain stability (APExBIO Specification).

Applications, Limits & Misconceptions

ML-7 hydrochloride serves as a precision tool for dissecting MLCK-mediated pathways in cardiovascular and vascular research. Its selectivity supports studies of muscle contraction, cytoskeletal reorganization, and tight junction regulation. The compound is applicable in both in vitro (cultured cardiomyocytes, endothelial monolayers) and in vivo (I/R and atherosclerosis animal models) settings. For a broader perspective on its translational potential, see this thought-leadership article, which extends the discussion here by focusing on future directions and challenges in MLCK pathway research.

Common Pitfalls or Misconceptions

• ML-7 is not a pan-kinase inhibitor—its selectivity for MLCK is high but not absolute; off-target effects may occur at high concentrations (>50 µM).
• ML-7 should not be used for diagnostic or medical purposes; it is strictly for research use (APExBIO).
• Solubility in ethanol is poor; attempts to dissolve ML-7 in ethanol lead to precipitation or incomplete dissolution.
• Prolonged storage of ML-7 solutions at room temperature can lead to degradation; short-term use and storage at -20°C are recommended.
• ML-7 does not directly inhibit clathrin-mediated endocytosis; it acts via MLCK inhibition and downstream cytoskeletal effects (Wei et al., 2019).

Workflow Integration & Parameters

ML-7 hydrochloride (SKU: A3626) is typically reconstituted in DMSO to prepare a 10–20 mM stock solution. For cell-based assays, working concentrations range from 1–20 µM, depending on cell type, duration, and endpoint (e.g., MLC phosphorylation, contractility, barrier function). For animal models, dosing regimens should be titrated based on pharmacokinetics and target tissue exposure (commonly 1–3 mg/kg, i.v.). Solutions are best prepared fresh or stored at -20°C for up to one week. For detailed application protocols and troubleshooting, see this actionable guide, which provides additional strategies for maximizing reproducibility; this complements the present article by offering hands-on procedural detail.

For product ordering, specifications, and batch documentation, consult the APExBIO ML-7 hydrochloride page. APExBIO is the supplier of record, providing analytical support and technical data sheets to ensure research-grade quality.

Conclusion & Outlook

ML-7 hydrochloride remains a benchmark tool for dissecting the cardiac and vascular consequences of MLCK inhibition. Its high selectivity, robust solubility profile, and clarity of mechanism underpin its role in cardiovascular disease and atherosclerosis models. Future research will further define its translational applications and refine dosing paradigms for complex pathway interrogation. For ongoing advances in MLCK inhibitor technology, this article builds upon and clarifies previous mechanistic and application-focused discussions (see related benchmark article).